PetVivo Holdings: Advancing Animal Health with Spryng, Precise PRP, and AI Vet Platform

Expanding Regenerative Animal Health

• 💡 PetVivo is onboarding clinics and educating them on its Spryng with OsteoCushion Technology and Precise PRP products.
• 🎯 The goal is to demonstrate how these products offer superior patient care and serve as profitable additions for veterinary clinics.
• 🚀 Spryng is highlighted as a product that can be used sooner in treatment, potentially delaying or preventing the need for surgery.

Spryng Technology and Clinical Application

• 🔬 Spryng addresses the root cause of osteoarthritis and joint lameness by correcting defects in the synovium, restoring proper joint function.
• ⏱️ Unlike other products requiring multiple injections, Spryng provides benefits for at least a year with a single injection.
• 🎓 Education is key to shifting veterinarian perception from Spryng as a last resort to a first-use product, supported by peer-reviewed articles and real-world results from over 12,000 injected animals.

From Human Medical Device to Animal Care

• 🏥 The Spryng product was initially developed at the Mayo Clinic with significant funding from the Department of Defense and NIH for regenerative medicine and drug delivery.
• 🧬 Ongoing studies with the University of Connecticut are exploring the regeneration of cartilage using a nano fiber and Spryng particles, potentially leading to human applications.
• 💰 The market for joint replacements is substantial ($33 billion annually), with lameness and osteoarthritis combined representing a $110 billion market, indicating significant potential for minimally invasive solutions like Spryng.

AI-Powered Veterinary Platform

• 📱 PetVivo is launching an AI-powered platform that includes a B2C app for pet owners to monitor their pet's health and a B2B application for veterinarians.
• ⏱️ The AI platform aims to reduce veterinary onboarding time by up to 80% and client acquisition costs by as much as 90%.
• 📊 It enhances diagnostics, provides owner-friendly explanations of conditions, and suggests at-home treatment participation, fostering better animal healthcare and lower costs.

Future Outlook and Milestones

• 🚀 The company is focused on expanding the adoption of its regenerative technologies and AI platform in the veterinary market.
• 📈 Key milestones for investors include the ongoing development and potential FDA filing for human applications, the full launch of the AI platform for B2B use, and the publication of peer-reviewed studies.
• 🌍 The long-term vision is to provide better healthcare and lower costs for companion animals, with the potential to extend these advancements into human applications.